Why the study?
The relative importance of excess aldosterone versus mineralocorticoid receptor overactivation in CKD progression remains uncertain, and definitive evidence demonstrating that aldosterone synthase inhibitors reduce hard renal and cardiovascular outcomes is lacking.
Do aldosterone synthase inhibitors improve systolic blood pressure, albuminuria, and renal and cardiovascular outcomes in patients with hypertension and chronic kidney disease?
Do aldosterone synthase inhibitors improve systolic blood pressure, albuminuria, and renal and cardiovascular outcomes in patients with hypertension and chronic kidney disease?
Second-generation aldosterone synthase inhibitors effectively reduce blood pressure and albuminuria in chronic kidney disease, but remain an investigational strategy due to hyperkalemia risks, the discontinuation of the phase III EASi-KIDNEY trial, and a lack of definitive hard outcome data.
Answers are grounded in this paper and cite their sources.
Hyperkalemia risk without proven hard outcomes cautions aldosterone synthase inhibitor use in CKD; challenges phase II promise.
Chronic kidney disease (CKD) is a growing global health burden closely linked to diabetes, hypertension and increased cardiovascular risk. The persistent activation of the renin–angiotensin–aldosterone system contributes to disease progression. Aldosterone, acting through mineralocorticoid receptors (MRs), promotes sodium retention and blood pressure elevation, but also drives inflammation, fibrosis, albuminuria and structural remodeling in renal and cardiovascular tissues. Emerging evidence suggests additional MR-independent mechanisms and alternative pathways of MR activation, further complicating its pathophysiological role. Aldosterone synthase inhibitors (ASIs) have been developed to suppress aldosterone production upstream by targeting aldosterone synthase-CYP11B2. Second-generation agents including baxdrostat, lorundrostat and vicadrostat, demonstrate improved selectivity compared with earlier compounds and have advanced through a phase II clinical evaluation in patients with hypertension and CKD. Across studies, ASIs achieved effective aldosterone suppression, reductions in systolic blood pressure and favorable effects on albuminuria. However, hyperkalemia emerged as a clinically relevant safety concern, particularly in CKD populations, challenging the expectation of a clearly superior electrolyte profile compared with MR antagonists. The relative importance of excess aldosterone versus MR overactivation in CKD progression remains uncertain. While upstream inhibition is mechanistically attractive and may offer theoretical advantages, definitive evidence demonstrating reductions in hard renal and cardiovascular outcomes is lacking. The discontinuation of the phase III EASi-KIDNEY trial provides an important negative signal regarding vicadrostat in the studied setting. However, in the absence of complete published results, this discontinuation should not be interpreted as definitive evidence of treatment inefficacy or generalized to ASIs as a drug class. Once the results from the EASi-KIDNEY trial are published, together with the data from ongoing outcome-driven trials, the therapeutic value of ASIs will be better understood. At present, ASIs represent a scientifically rational but investigational strategy in CKD management, pending definitive confirmation of long-term efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Polenus et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: